机构：[1]Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China.[2]Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, Zhejiang 325000, China.[3]Department of Radiology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.[4]Department of Radiology and Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.四川大学华西医院[5]The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, Guangdong 518057, China.[6]Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.[7]Zhejiang Engineering Research Center for Innovation and Application of Intelligent Radiotherapy Technology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
The leakage of gadolinium ions (Gd3+) from commercial Gd3+-based contrast agents (GBCAs) in patients is currently the major safety concern in clinical magnetic resonance imaging (MRI) scans, and the lack of task-specific GBCAs limits its usage in the early detection of disease and imaging of specific biological regions. Herein, ultrastable GBCAs were constructed via decorating chiral Gd-DOTA with a phenylic analogue to one of the pendent arms, and the stability constant was determined as high as 27.08, accompanied by negligible decomplexation in 1 M of HCl over 2 years. A hepatic-specific chiral Gd-DOTA was screened out as a potential alternative to commercial Gd-EOB-DTPA, while combination with functional molecules favored chiral Gd-DOTA as tumor targeting probes. Therefore, the novel chiral Gd-DOTA is believed to be an ideal platform for designing the next generation of GBCAs for various clinical purposes due to its outstanding inert nature.
基金：
This work was financially supported by the National Natural
Science Foundation of China (22075281, 32071376, and
22105201), Zhenjiang Provincial Natural Science of Foundation
of China (LZ21B010001), University of Chinese
Academy of Science (WIUCASQD2020008); Wenzhou
Fund of Science and Technology (2021Y0163); Anhui
Laboratory of Molecule-Based Materials (Fzj21002); and
The Innovation Research Project of Sichuan University
(2022SCUH0013).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|1 区医学
小类|1 区药物化学
最新[2023]版：
大类|1 区医学
小类|1 区药物化学
第一作者：
第一作者机构：[1]Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China.[2]Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, Zhejiang 325000, China.
共同第一作者：
通讯作者：
通讯机构：[1]Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China.[2]Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, Zhejiang 325000, China.[6]Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.[7]Zhejiang Engineering Research Center for Innovation and Application of Intelligent Radiotherapy Technology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.
推荐引用方式(GB/T 7714)：
Xu Weiyuan,Ye Xinjian,Wu Min,et al.Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents[J].Journal of medicinal chemistry.2023,doi:10.1021/acs.jmedchem.3c01183.
APA：
Xu Weiyuan,Ye Xinjian,Wu Min,Jiang Xin,Hugo Tse Lik Hang...&Dai Lixiong.(2023).Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents.Journal of medicinal chemistry,,
MLA：
Xu Weiyuan,et al."Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents".Journal of medicinal chemistry .(2023)
医学